Piper Sandler Reiterates Overweight Rating on Definium Therapeutics Inc (DFTX)

Piper Sandler analyst David Amsellem reiterated an Overweight rating and $49.00 price target on Definium Therapeutics Inc (NASDAQ: DFTX).

The analyst commented: "We attended Definium's analyst/investor day. Key topics included the DT120 patient and practitioner experience (e.g., patient monitoring) and clinical development of the product beyond generalized anxiety disorder (GAD) and major depressive disorder (MDD) (i.e., a Phase III study in post-traumatic stress disorder (PTSD) is in the works). Taking a step back, we continue to believe that management's development approach regarding DT120 (i.e., a broader approach to anxiety/mood disorders as opposed to a narrower focus on treatment-resistant populations) is logical (particularly in the context of the absence of new approvals in GAD for nearly 20 years). Beyond that, given the body of data surrounding the product to date, we remain confident in clear Phase III success in both GAD and MDD (refer to our report on 4/9/26 for more details). We reiterate our Overweight rating and $49 PT."

For an analyst ratings summary and ratings history on Definium Therapeutics Inc click here. For more ratings news on Definium Therapeutics Inc click here.

Shares of Definium Therapeutics Inc closed at $23.08 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Cosa Resources announces C$5 million bought deal private placement
• Greenway Technologies board member Raymond Wright resigns